The FMS-like tyrosine kinase-3 (FLT3) gene is the most commonly mutated gene in acute myeloid leukemia (AML), and patients carrying internal tandem duplication (ITD) mutations have a poor prognosis. Long-term inhibition of FLT3 activity in these patients has been elusive. To provide a more complete understanding of FLT3 biology, a mass spectroscopy-based screen was performed to search for FLT3-interacting proteins. The screen identified dedicator of cytokinesis 2 (DOCK2), which is a guanine nucleotide exchange factor for Rho GTPases, and its expression is limited to hematolymphoid cells. We show that DOCK2 is expressed in leukemia cell lines and primary AML samples, and DOCK2 co-immunoprecipitates with wild-type FLT3 and FLT3/ITD. Knockdown (KD) of DOCK2 by shRNA selectively reduced cell proliferation and colony formation in leukemia cell lines with increased FLT3 activity, and greatly sensitized these cells to cytarabine treatment, alone and in combination with FLT3 tyrosine kinase inhibitors. DOCK2 KD in an FLT3/ITD-positive leukemia cell line also significantly prolonged survival in a mouse xenograft model. These findings suggest that DOCK2 is a potential therapeutic target for novel AML treatments, as this protein regulates the survival of leukemia cells with elevated FLT3 activity and sensitizes FLT3/ITD leukemic cells to conventional antileukemic agents.
INTRODUCTION
Acute myeloid leukemia (AML) is a hematologic malignancy characterized by clonal expansion of myeloid blasts in the bone marrow (BM) and other tissues. 1 The FMS-like tyrosine kinase-3 (FLT3) receptor gene is the most commonly mutated gene in AML, 2 and the most frequent of these mutations is an internal tandem duplication (ITD) in the juxtamembrane domain. 3, 4 FLT3/ ITD mutations result in constitutive activation of the kinase, and patients with FLT3/ITD AML have a particularly poor prognosis, 5, 6 making inhibition of this tyrosine kinase an attractive therapeutic target. 7 However, despite continuing progress in the development of FLT3 inhibitors, long-term inhibition of FLT3 activity in AML patients remains elusive. 8, 9 In order to achieve a better understanding of FLT3 biology and to develop more effective strategies for the inhibition of FLT3 activity and treatment of acute leukemia with activating mutations of FLT3, we performed a screen that utilized immunoprecipitation (IP) coupled with mass spectroscopy to identify proteins that interact with FLT3 and FLT3/ITD in human leukemia cell lines. Numerous candidate interactors were identified, including proteins involved in cell motility and proliferation, the regulation of reactive oxygen species (ROS), signal transduction in hematopoietic malignancies and intracellular trafficking. One of the proteins identified in this screen was dedicator of cytokinesis 2 (DOCK2).
The DOCK family of proteins act as guanine nucleotide exchange factors for Rho GTPases, including Rac1. 10 Rac1 is widely expressed in both neoplastic and normal epithelial and hematolymphoid cells, and is important for cell motility and growth. 11, 12 We have previously shown that FLT3/ITD activation results in increased ROS production partly through Rac1 activation. 13 DOCK2 activates Rac1 but, unlike Rac1, DOCK2 expression is limited to hematopoietic tissues.
14 DOCK2 is known to regulate several crucial processes, including lymphocyte migration, 14 activation and differentiation of T cells, 15 cell-cell adhesion 16 and BM homing of various immune cells. 17, 18 Since DOCK2 expression is limited to hematopoietic tissues, it is a particularly attractive drug target for the treatment of AML, since it would theoretically limit side effects by avoiding Rac1 inhibition in non-hematolymphoid tissues.
Here we confirm that DOCK2 interacts with FLT3 in both cell lines and primary leukemic cells. In cells with elevated FLT3 activity, knockdown (KD) of DOCK2 results in decreased cell proliferation and increased susceptibility to cytarabine (ARA-C), both in the presence and absence of FLT3 inhibitors. Additionally, mice transplanted with human leukemia cell lines that express mutated FLT3 show significantly increased survival when DOCK2 expression is suppressed. These findings suggest that targeting the Rac1 pathway via DOCK2 inhibition may be a feasible and novel therapeutic strategy for the treatment of FLT3/ITD acute leukemias.
(Manassas, VA, USA). All cells were freshly thawed from stocks that were confirmed to be free of mycoplasma and frozen in 2010.
Peripheral blood (PB) and BM samples from human AML patients were collected under a protocol approved by the Johns Hopkins Medicine Institutional Review Board. Proper consent was obtained for all subjects in accordance with the Declaration of Helsinki. Viable mononuclear cells were isolated from freshly thawed samples by Ficoll centrifugation. Human normal CD34+ cells were isolated using magnetically labeled microbeads (Miltenyi Biotec, San Diego, CA, USA) bound to MS columns (Miltenyi Biotec).
Reagents
Cytarabine (ARA-C) was obtained from Sigma-Aldrich (St Louis, MO, USA). Sorafenib, quizartinib (AC220) and lestaurtinib (CEP701) were obtained from LC Laboratories (Woburn, MA, USA). NSC23766 was obtained from Tocris Bioscience (Ellisville, MO, USA).
IP and western blotting
IP experiments were performed as previously described. 19 Each IP experiment has been replicated at least three times. Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA) and detected by indicated antibodies followed by horseradish peroxidaseconjugated secondary antibodies and chemiluminescence. Anti-FLT3 (480), anti-DOCK2 (365242), anti-β-Actin (8432) and anti-β-Tubulin (5274) antibodies were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Antibodies against phospho-FLT3 (Y589/591; 3474), phospho-STAT5 (Y694; 9351) and STAT5 (9363) were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibodies against phospho-tyrosine (05-321) were obtained from Millipore (Billerica, MA, USA). Rac1 activation (Rac1-GTP) was assessed using the Rac1 activation assay (Millipore), and the G-LISA activation assay (Cytoskeleton, Inc., Denver, CO, USA). Quantifications of band densities were performed with a GS-900 Calibrated Densitometer (Bio-Rad) according to the manufacturer's instruction. For MG132 treatment, cells were incubated with 5 μM MG132 (Sigma-Aldrich) at 37°C for 1 h prior to cell lysis. For DSP treatment, cells were incubated with 1 mM dithiobis(sccinimidyl propionate) (DSP; ThermoFisher Scientific, Waltham, MA, USA) at 4°C for 1.5 h prior to cell lysis.
Mass spectroscopy
Cells were solubilized using NP-40 (1%), and the post-nuclear supernatant was immunoprecipitated with the anti-FLT3 antibody. For each sample, the immunoprecipitated proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis on 4-12% gradient gels, and the lanes were excised and sliced into bands. The bands were then proteolytically digested and the peptides subjected to mass spectroscopic analysis (Tackett Laboratory, University of Arkansas for Medical Sciences, Little Rock, AR, USA). The results were uploaded into Scaffold 4 for viewing protein and peptide information.
Cell transduction
Stable cell lines with KD of DOCK2 were created using shRNA directed against DOCK2 from The RNAi Consortium (antisense: TTCTCAACTG TCACTTCCTTG; Sigma-Aldrich). Cells were transduced with lentiviral vectors (pLKO1) with shRNA directed against DOCK2 and GFP (CCGGTACAACAGCCACAACGTCTATCTC-GAGATAGACGTTGTGGCTGTTGTAT TTTT) under puromycin selection (2 μg/ml; Sigma-Aldrich).
Inducible cell lines were prepared using lentiviral pTRIPZ vectors expressing shRNAs against human DOCK2 (V3THS_358138: TTCTCA ACTGTCACTTCCT and V3THS_358139: TGATATTCACACAGCATCA) and scrambled control shRNA (RHS4743: TGCTGTTGACAGTGAGCGATCTCGCT TGGGCGAGAGTAAGTAGTGAAGCCACAGATGTACTTACTCTCGCCCAAGCGA-GAGTGCCTACTGCCTCGGA; Thermo Scientific). Cells were transduced according to the manufacturer's instructions, cultured in the presence of 5 μg/ml puromycin and sorted for high RFP expression 48 h after doxycycline (1 μg/ml) induction using FACSAria (BD Biosciences, San Jose, CA, USA).
Cell culture assays
Apoptosis assays were performed according to the manufacturer's instructions (BD Biosciences) using Annexin V-APC and 7-Aminoactinomycin D. Late apoptosis was defined as cells positive for both 7-Amino-actinomycin D and Annexin V. The IC50 values of the drugs for each cell line were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide assays according to the manufacturer's instruction (Roche Diagnostics, Indianapolis, IN, USA) (Supplementary Figure S3) . For cells expressing inducible shRNA, the expression of shRNA was induced with doxycycline (1 μg/ml; Sigma-Aldrich) 24 h prior to the start of the assay.
To measure cell proliferation, cells in the logarithmic growth phase were diluted, placed in a 24-well plate in triplicate and cell densities were measured.
The colony formation assay was performed using MethoCult H4230 (Stem Cell Technologies, Vancouver, BC, Canada) according to the manufacturer's instruction. Each culture dish started with 200 cells.
The levels of ROS in cells were measured using ROS detection reagent CM-H 2 DCFDA (ThermoFisher Scientific) according to the manufacturer's instruction.
Each data point represents the average of three biological replicates.
Mouse transplantation experiments NSG (NOD/Shi-scid/IL-2Rγ null ) mice (in-house breeding; female, 4-6 weeks) were sublethally irradiated (250 rads), and each mouse was injected with 0.6 × 10 6 cells via lateral tail vein. Engraftment was assessed by flow cytometric measurement of human and mouse CD45 expression on the cell surface (APC mouse anti-human CD45 and FITC rat anti-mouse CD45; BD Biosciences). Fifteen mice were transplanted with MV4;11-C cells, seven of which were assessed for engraftment. Ten mice were transplanted with MV4;11-KD cells, five of which were assessed for engraftment. For REH-C and REH-KD cells, five mice were transplanted with each cell line, and all were assessed for engraftment. The sample sizes were chosen based on efficiency of resource use, past experience with similar experiments and pilot experiments to determine the effect size. No animal was excluded from the analysis, randomization was not used and the investigator was not blinded. All animal procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Institute of Health, Bethesda, MD, USA) and were approved by the Institutional Animal Care and Use Committee at Johns Hopkins University.
Statistics
Statistical analysis was performed with Student t-test (two-tailed), repeated measure ANOVA and log-rank test using GraphPad software (GraphPad Software, Inc., La Jolla, CA, USA). All data are presented as the mean ± s.e.m. The variance was similar between all groups being compared. P-values o0.05 were considered to be statistically significant.
RESULTS

DOCK2 interacts with FLT3 in hematopoietic cells
An antibody that interacts with both wild type and ITD-mutant FLT3 was used to perform IPs from two different human leukemia cell lines: Molm14 and TF-1. The Molm14 cell line was derived from a patient with acute monocytic leukemia, 20 and contains both wild-type FLT3 and FLT3/ITD alleles. IP with rabbit serum was used as a negative control for this experiment. We also performed IP from a TF-1 cell line that was engineered to express an FLT3/ITD construct that had been initially identified in a patient with AML. 21 The TF-1 parental cell line, which was derived from a patient with erythroid leukemia 22 and lacks expression of FLT3, was used as a control. Following IP, a mass spectroscopy-based screen was performed to identify proteins that potentially interact with FLT3/ ITD (Supplementary Figures S1A-C) .
Through this screen, we identified a panel of proteins that co-IP with the antibody directed against FLT3, but were absent from the control lanes. DOCK2 was one of the potential interactors that were identified in IP from both the Molm14 and TF-1:FLT3/ITD cell lines (Supplementary Figure S1C) . In the Molm14 screen, 16 DOCK2 peptides were identified in IP from Molm14 cells, and 1 DOCK2 peptide was identified in the control lane. In the TF-1 screen, six DOCK2 peptides were identified in IP from the TF-1: FLT3/ITD cells, and no DOCK2 peptides were identified in the IP DOCK2 and FLT3/ITD AML M Wu et al from the parental TF-1 cells. We verified that DOCK2 was expressed in various established hematopoietic cell lines (Figure 1a) , including K562 cells (derived from an erythroleukemia arising from chronic myeloid leukemia that lacks expression of FLT3), 23 Molm14 cells, Ba/F3 cells (derived from a murine pro-Bcell line) that were engineered to express the most frequent activating point mutation in the kinase domain (D835Y), 24 HB11;19 cells (derived from a patient with acute leukemia carrying a D835H point mutation) 25 (Supplementary Figure S2) , SEM K2 cells (derived from a human leukemia overexpressing wild-type FLT3 that is constitutively activated by FL autocrine signaling) 26 and MV4;11 cells (derived from a biphenotypic B/myeloid leukemia that expresses homozygous FLT3/ITD). 27 The BM stroma cell line HS5 was used as a negative control. DOCK2 was expressed in all primary AML samples tested (Figure 1b) , including AMLs that lack FLT3 mutations and those with FLT3/ITD mutations. DOCK2 was also expressed in CD34+ cells from normal BM, albeit at a lower level than in the primary AML samples.
Co-IP experiments using antibodies against DOCK2 and FLT3 revealed that the two proteins co-IP in cell lines expressing FLT3/ ITD mutations (Molm14 and MV4;11), FLT3 D835 mutation (HB11;19) and activated wild-type FLT3 (SEM K2) ( Figure 1c Figure S1C) , in many of the cell lines, the IP was relatively weak, likely reflecting the low level of expression of these proteins in many of these cell lines and the fact that this interaction is most likely to be transient and dynamic. Accordingly, the level of DOCK2 co-immunoprecipitating with FLT3 significantly increased when Molm14 cells were treated with the proteasome inhibitor MG132 or the protein cross-linker DSP prior to cell lysis (Supplementary Figure S2B) . Interestingly, in western blot studies DOCK2 appears to predominantly interact with the unphosphorylated form of wild-type FLT3, FLT3/D835 and FLT3/ITD, regardless of whether FLT3 was stimulated with FLT3 ligand (FL; 10 ng/ml) or inhibited by sorafenib (25 nM) (Supplementary Figure S2) .
KD of DOCK2 leads to reduced cell proliferation and colony formation in cell lines with elevated FLT3 activity We next examined the effects of reduced expression of DOCK2 on cell viability. Efficient KD of DOCK2 expression was achieved by either stable expression of an shRNA against DOCK2 (Figure 2a) , or induced expression of shRNAs against DOCK2 in the presence of doxycycline (Figure 2b) (Figure 2c) . Additionally, decreased expression of DOCK2 led to a statistically significant (Figure 2d ), suggesting that DOCK2 is involved in STAT5 activation resulted from activated FLT3 signaling. The proliferation rate of cells with elevated FLT3/ITD activity (MV4;11) was markedly reduced upon stable KD of DOCK2 expression, and cells with relatively lower FLT3 activity (Molm14, HB11;19) and cells expressing wild-type FLT3 (REH and SEM K2) also showed significant reduction, while cells with no FLT3 activity (K562) exhibited no difference in the cell proliferation rate (Figure 3a) . Similarly, the proliferation rate of MV4;11 cells was significantly reduced using inducible anti-DOCK2 shRNAs, while no difference was observed in TF-1 cells, which do not express FLT3 (Figure 3b ).
To explore potential effects on clonability, KD of DOCK2 was performed in 293T, SEM K2, HB11;19 and MV4;11 cell lines followed by plating in methylcellulose. Cell lines with elevated FLT3 activity (MV4;11 and SEM K2) exhibited a significant reduction in colony-forming capacity in the presence of stably expressed anti-DOCK2 shRNA, while there was modest reduction in HB11;19 cells. No difference in colony formation was observed in 293T cells, which express neither FLT3 nor DOCK2 (Figure 3c ). DOCK2 KD also resulted in smaller, more compact colonies in FLT3-expressing cells, while no such morphologic variability was observed in 293T cells (Figure 3d ). These results indicate that DOCK2 plays a role in cell proliferation and colony formation in cells with elevated FLT3 activity. 
DOCK2 and FLT3/ITD AML M Wu et al
Decreased DOCK2 expression in cells with elevated FLT3 activity increases sensitivity to cytarabine treatment Cytarabine (ARA-C) is a chemotherapeutic agent that is widely used during both induction and consolidation regimens in the treatment of AML. 29 We investigated the effect of DOCK2 KD on leukemic cells in the presence of ARA-C. Cells with modest FLT3 activity (Molm14, HB11;19, REH) or no FLT3 activity (K562) showed no significant change or only modest response to ARA-C treatment upon KD of DOCK2; however, cells with elevated FLT3 activity (MV4;11 and SEM K2) exhibited significantly increased apoptosis in the presence of ARA-C when the expression of DOCK2 was stably reduced (Figure 4a) . Similar results were found upon doxycycline treatment in cell lines expressing inducible DOCK2 shRNAs. The percent of late apoptosis was increased in MV4;11 cells treated with ARA-C when KD of DOCK2 was induced, while no difference was observed in TF-1 cells expressing the same shRNAs ( Figure 4b ). MV4;11 cells expressing an anti-DOCK2 shRNA exhibited reduced viable cell counts upon ARA-C treatment, while cells stably expressing a control shRNA continued to proliferate, albeit slowly (Figure 4c ). In contrast, suppression of DOCK2 expression resulted in no observable difference in the response of REH cells to ARA-C treatment.
As the effect of DOCK2 KD on the sensitivity of cells to ARA-C treatment was most pronounced in MV4;11 and SEM K2 cells, both of which have elevated FLT3 activity, we next investigated the effect of FLT3 inhibition on the sensitivity of cells to ARA-C treatment. To better observe the combinatorial effect of FLT3 tyrosine kinase inhibitors (TKI) and ARA-C, cells were treated with lower doses of ARA-C and TKI, either of which exhibited modest Figure 3 . Knockdown of DOCK2 results in decreased cell proliferation and decreased colony formation in cell lines that express FLT3. (a) Cells with stable expression of anti-DOCK2 shRNA were seeded at less than 0.1 million cells/ml to maximize the observable difference in proliferation, and counted every 24 h. Cell lines expressing FLT3 showed decreased cell proliferation when expression of DOCK2 was reduced (REH, HB11;19, Molm14 and SEM K2, **P ⩽ 0.01), and pronounced changes were observed in MV4;11 cells (***P = 0.0002). Assays were performed in triplicate. (b) Induced expression of two shRNAs directed against DOCK2 in MV4;11 cells also resulted in decreased cell proliferation in assays that were performed in triplicate. TF-1 cells that lack FLT3 expression served as a negative control. (c) Colony formation assays performed in triplicate showed that stable knockdown of DOCK2 led to significantly decreased colony formation in SEM K2 (**P ⩽ 0.01) and MV4;11 cells (***P ⩽ 0.001). HB11;19 cells showed a trend in keeping with the SEM K2 and MV4;11 cells, but the difference was not statistically significant. HEK 293T cells that lack both DOCK2 and FLT3 were used as a negative control. Colony numbers were counted 2 weeks after plating. (d) Qualitative changes in colony morphology were seen in cell lines that express FLT3. Images were acquired at × 40 using a Nikon Eclipse Ti microscope at room temperature 2 weeks after plating. All images are shown at the same scale. . Statistically significant differences were seen between ARA-C alone and ARA-C+SB (**P ⩽ 0.01), ARA-C +CEP701 (**P ⩽ 0.01) and ARA-C+AC220 (***P ⩽ 0.001), as well as SB alone and ARA-C+SB (**P ⩽ 0.01), CEP701 and ARA-C+CEP701 (***P ⩽ 0.001), and AC220 and ARA-C+AC220 (***P ⩽ 0.001). All assays were performed in triplicate. 
DISCUSSION
We have shown that the Rho guanine nucleotide exchange factor DOCK2 interacts with FLT3, and that a decrease in DOCK2 expression inhibits the survival of leukemic cells that express activated FLT3 in both in vitro and in vivo models. These findings implicate DOCK2 as a potential druggable target for acute leukemias with elevated FLT3 activity.
DOCK2 is a tissue-specific guanine nucleotide exchange factor that mediates GTP-GDP exchange for Rac1 and Rac2. The Rho GTPases have been considered as potential druggable targets for the treatment of various tumors since misregulation of these proteins, particularly Rac1, has been described in both hematopoietic neoplasms and epithelial neoplasms including breast, lung, oral squamous cell and gastric carcinomas. [30] [31] [32] [33] [34] While the function of Rac1 in neoplastic processes has been investigated, Rac1 signaling is also important for non-oncologic processes including endothelial function.
Small molecular Rac1 inhibitors are available, including NSC23766, which inhibits the Rac-specific guanine nucleotide exchange factors Trio or Tiam1; 35 however, due to the widespread expression and protean cellular functions of Rac1, the potential side effect profile is worrisome. Targeting tissue-specific Rho effectors, such as DOCK2, may help to improve the selectivity of Rac1 inhibition, making it a feasible drug target. Interestingly, DOCK2 KD and NSC23766 showed similar effects on Rac1 activity, ROS levels and sensitivity to ARA-C treatment in MV4;11 cells (Supplementary Figure S4) , confirming that the antileukemic effects of DOCK2 inhibition in FLT3/ITD-positive leukemic cells were exerted through the inhibition of Rac1 pathway. DOCK2 inhibitors are not currently widely available, although small molecular inhibitors of DOCK2 have been reported in the literature. 36, 37 Additionally, the screening of preexisting drug libraries for potential DOCK2 inhibitors may be warranted.
While Rac1 has been extensively studied, DOCK2 is not particularly well-characterized. Most of the research on DOCK2 has focused on immunologic research, as DOCK2 deficiency has been described in patients with inborn errors of T-cell immunity, 38 DOCK2-deficient mice show abnormalities of the immune system, 39, 40 and abrogation of DOCK2 expression is associated with decreased formation and proliferation of mature B-cell lymphomas. 41 Recent reports have described mutations in DOCK2 that are associated with colorectal and esophageal carcinoma; 42, 43 however, these studies are descriptive and the functional consequences of the DOCK2 mutations found in solid tumors is unclear.
One clue as to the mechanism of action of downregulation of DOCK2 in FLT3/ITD cells is the concomitant decrease in STAT5 activity. Of note, STAT5 activity is associated with decreased survival in patients with FLT3/ITD AML. 44 FLT3 has been shown to directly phosphorylate STAT5; 45 however, STAT5 activation can also be mediated by alternative pathways, including FLT3/ITD-mediated activation of FAK with resultant activation of Tiam1, Rac1, PAK1 and finally phosphorylation of STAT5. 46 Other mechanistic possibilities for DOCK2 inhibition include the changes in the generation of ROS, 47 changes in DNA damage repair pathways, 48 and alterations in the interaction between the leukemic cells and the BM microenvironment. 49 Taken together, our findings suggest that DOCK2 inhibition may provide a feasible strategy for Rac1 inhibition in hematopoietic neoplasms, and could improve the efficacy of current therapeutic regimens for FLT3/ITD acute leukemia.
